SOUTH EASTON, Mass., May 28, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the 3^rd Annual Marcum MicroCap Conference on Thursday, May 29^th, at 2:30 pm EDT. The Conference is being held at the Grand Hyatt Hotel in New York City.

Mr. Schumacher's presentation will be webcast and may be viewed live at the following link (http://wsw.com/webcast/marcum2/PBIO) and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com).

About Marcum LLP and the Marcum MicroCap Conference

The Marcum Microcap Conference will allow institutional investors, sell-side analysts, and investment bankers the opportunity to consider the investment prospect being showcased by the next generation of up-and-coming microcap companies in seven industries, including the Life Sciences. The conference is expected to draw more than 1,000 attendees.

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in more than 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services, LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC. For more information, visit www.marcumllp.com.  

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.    

For more information about PBI and this press release, please click on the following website link:  
http://www.pressurebiosciences.com

SOURCE Pressure BioSciences, Inc.